Sutherland Isabella, Ho Ming-Fen, Croarkin Paul E
University of Vermont Larner College of Medicine, Burlington, Vermont, USA.
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
J Child Adolesc Psychopharmacol. 2025 Apr;35(3):118-125. doi: 10.1089/cap.2024.0082. Epub 2025 Jan 6.
Interest in psychedelic therapies for adults is rapidly growing, with substances like 3,4-methylenedioxymethamphetamine for posttraumatic stress disorder, psilocybin for treatment-resistant depression, and lysergic acid diethylamide for generalized anxiety disorder showing promise. However, research on these therapies in children and adolescents is limited, with no recent trials. Despite this lack of scientific exploration, adolescents may still experiment with these substances for both recreational and therapeutic purposes as accessibility continues to increase. This raises significant concerns, as adolescents are a vulnerable population requiring heightened caution and safety measures. Therefore, we advocate for structured, safe, and well-controlled exploration of psychedelic therapies in adolescents.
成人对迷幻疗法的兴趣正在迅速增长,诸如用于治疗创伤后应激障碍的3,4-亚甲基二氧甲基苯丙胺、用于治疗抵抗性抑郁症的裸盖菇素以及用于广泛性焦虑症的麦角酸二乙酰胺等物质都显示出了前景。然而,针对儿童和青少年的这些疗法的研究有限,且近期没有相关试验。尽管缺乏科学探索,但随着可及性不断增加,青少年仍可能出于娱乐和治疗目的尝试这些物质。这引发了重大担忧,因为青少年是弱势群体,需要更高的谨慎和安全措施。因此,我们主张对青少年的迷幻疗法进行结构化、安全且严格控制的探索。